JP2005519893A - Cns疾患の治療において使用するためのプレグナンステロイド - Google Patents

Cns疾患の治療において使用するためのプレグナンステロイド Download PDF

Info

Publication number
JP2005519893A
JP2005519893A JP2003559519A JP2003559519A JP2005519893A JP 2005519893 A JP2005519893 A JP 2005519893A JP 2003559519 A JP2003559519 A JP 2003559519A JP 2003559519 A JP2003559519 A JP 2003559519A JP 2005519893 A JP2005519893 A JP 2005519893A
Authority
JP
Japan
Prior art keywords
3beta
hydroxy
5alpha
pregnane
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003559519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519893A5 (cg-RX-API-DMAC7.html
Inventor
ベクストルム,トルビエーン
ルンドグレン,ペール
ワン,ミン−デ
ヨハンソン,インガ−マー
Original Assignee
ウメクライン アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウメクライン アーベー filed Critical ウメクライン アーベー
Publication of JP2005519893A publication Critical patent/JP2005519893A/ja
Publication of JP2005519893A5 publication Critical patent/JP2005519893A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003559519A 2001-12-27 2002-12-20 Cns疾患の治療において使用するためのプレグナンステロイド Pending JP2005519893A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104423A SE0104423D0 (sv) 2001-12-27 2001-12-27 Pregnane steroids and their use in the treatment of CNS disorders
PCT/SE2002/002423 WO2003059357A1 (en) 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009256620A Division JP5289281B2 (ja) 2001-12-27 2009-11-10 Cns疾患の治療において使用するためのプレグナンステロイド

Publications (2)

Publication Number Publication Date
JP2005519893A true JP2005519893A (ja) 2005-07-07
JP2005519893A5 JP2005519893A5 (cg-RX-API-DMAC7.html) 2006-01-19

Family

ID=20286518

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003559519A Pending JP2005519893A (ja) 2001-12-27 2002-12-20 Cns疾患の治療において使用するためのプレグナンステロイド
JP2009256620A Expired - Fee Related JP5289281B2 (ja) 2001-12-27 2009-11-10 Cns疾患の治療において使用するためのプレグナンステロイド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009256620A Expired - Fee Related JP5289281B2 (ja) 2001-12-27 2009-11-10 Cns疾患の治療において使用するためのプレグナンステロイド

Country Status (10)

Country Link
US (2) US7960367B2 (cg-RX-API-DMAC7.html)
EP (2) EP2275109B1 (cg-RX-API-DMAC7.html)
JP (2) JP2005519893A (cg-RX-API-DMAC7.html)
CN (3) CN101601674A (cg-RX-API-DMAC7.html)
AU (3) AU2002359202C1 (cg-RX-API-DMAC7.html)
CA (1) CA2468248C (cg-RX-API-DMAC7.html)
DK (1) DK1458399T3 (cg-RX-API-DMAC7.html)
ES (1) ES2394639T3 (cg-RX-API-DMAC7.html)
SE (1) SE0104423D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003059357A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507113A (ja) * 2014-01-29 2017-03-16 ウメクライン コグニション アーベー 肝性脳症の治療において使用するためのステロイド化合物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
DK1812009T3 (da) * 2004-11-18 2013-08-05 Umecrine Ab GABA-steroidantagonister og deres anvendelse til behandling af CNS-lidelser
EP2711372A1 (en) 2006-11-21 2014-03-26 Umecrine AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
JP5687287B2 (ja) 2010-01-14 2015-03-18 ウメクライン ムード エービー 改善された保存性及び溶解特性を有する3−ベータ−ヒドロキシ−5−アルファ−プレグナン−20−オンを含有する薬学的組成物
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
RU2667065C2 (ru) 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ab公司 新穎化合物
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
US10933014B2 (en) * 2017-01-09 2021-03-02 Asarina Pharma Ab Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
CN110430883A (zh) 2017-02-10 2019-11-08 阿沙里那制药公司 用于医学治疗的3β-羟基-5α-孕烷-20-酮
CN111918657A (zh) * 2018-04-05 2020-11-10 阿沙里那制药有限公司 用于治疗物质戒断障碍的gaba-a拮抗剂
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439900A (en) * 1993-02-25 1995-08-08 Bukusoglu; Cuneyt Methods and compositions for providing analgesia and enhanced anesthesia
WO1998050042A1 (en) * 1997-05-02 1998-11-12 American Home Products Corporation Pregnan-3-ol-20-ones
WO1999045931A1 (en) * 1998-03-11 1999-09-16 Baeckstroem Torbjoern Epiallopregnanolone in the treatment of cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
PT980381E (pt) 1997-05-02 2003-12-31 Wyeth Corp Sais farmaceuticamente aceitaveis de ester 3-sulfato de 5-alfa-pregn-16-en-3-beta-ol-20-ona com actividade de progesterona e uteis no tratamento de perturbacoes do snc
CN1254342A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 用作孕激素和治疗CNS疾病的5α-孕烷-3β,16α-二醇-20-酮3-硫酸酯的可药用盐
CZ20011343A3 (cs) 1998-10-13 2002-04-17 American Home Products Corporation Pregnanglukuronidy
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439900A (en) * 1993-02-25 1995-08-08 Bukusoglu; Cuneyt Methods and compositions for providing analgesia and enhanced anesthesia
WO1998050042A1 (en) * 1997-05-02 1998-11-12 American Home Products Corporation Pregnan-3-ol-20-ones
WO1999045931A1 (en) * 1998-03-11 1999-09-16 Baeckstroem Torbjoern Epiallopregnanolone in the treatment of cns disorders

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6009033596; PRINCE,R.J. et al: 'Differential antagonism by epipregnanolone of alphaxalone and pregnanolone potentiation of [3H]fluni' Neuropharmacology Vol.32, No.1, 1993, p.59-63 *
JPN6009033598; PRINCE,R.J. et al: '5-BETA PREGNAN-3-BETA-OL-20-ONE A SPECIFIC ANTAGONIST AT THE NEUROSTEROID SITE OF THE GABA-A RECEPTO' Neuroscience Letters Vol.135, No.2, 1992, p.273-275 *
JPN6010009957; CLARK,L.C. et al: 'Substrate specificity of cholesterol oxidase' Clinical Chemistry(Washington, DC, United States) Vol.26, No.5, 1980, p.678 *
JPN6010009960; KOKATE,T.G. et al: 'Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acid-evoked chloride curr' Journal of Pharmacology and Experimental Therapeutics Vol.270, No.3, 1994, p.1223-9 *
JPN6010009962; NAGATA,W. et al: 'Studies on total syntheses of steroids. XIII. Stereospecific total synthesis of dl-5alpha-pregnan-3beta-o' Tetrahedron Letters No.14, 1963, p.865-8 *
JPN6013024253; C.W.Thornber: 'Isosterism and Molecular Modification in Drug Design' Chemical Society Reviews Vol.8, No.4, 1979, p563-580
JPN6013024256; 橋田 充: '化学構造からみたプロドラッグの種類' Progress in Medicine Vol.5, No.7, 1985, p.2157-2161
JPN6013024542; E.F.LAMBERT et al: Br. J. Pharmacol. Vol.91, 1987, 484P
JPN6013024544; Pettey C.J. and Simmonds M.A.: 'Antagonism of 5beta-pregnan-3alpha-ol-20-one by its 3beta-isomer on GABA-evoked currents in cultured neuron' Fundam. clin. Pharmac. Vol.5, 1991, p384

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507113A (ja) * 2014-01-29 2017-03-16 ウメクライン コグニション アーベー 肝性脳症の治療において使用するためのステロイド化合物

Also Published As

Publication number Publication date
ES2394639T3 (es) 2013-02-04
US8119619B2 (en) 2012-02-21
AU2009201956B2 (en) 2010-11-25
CN101601674A (zh) 2009-12-16
EP1458399A1 (en) 2004-09-22
CA2468248C (en) 2011-08-16
EP2275109A2 (en) 2011-01-19
JP2010065052A (ja) 2010-03-25
DK1458399T3 (da) 2012-11-12
JP5289281B2 (ja) 2013-09-11
US7960367B2 (en) 2011-06-14
SE0104423D0 (sv) 2001-12-27
US20110098259A1 (en) 2011-04-28
AU2009201956A1 (en) 2009-06-11
CN1607954A (zh) 2005-04-20
WO2003059357A1 (en) 2003-07-24
CN100518741C (zh) 2009-07-29
US20050222099A1 (en) 2005-10-06
EP2275109A3 (en) 2011-10-12
AU2002359202B2 (en) 2009-02-19
AU2002359202C1 (en) 2011-03-31
CN101601675A (zh) 2009-12-16
AU2002359202A1 (en) 2003-07-30
EP1458399B1 (en) 2012-08-08
EP2275109B1 (en) 2013-07-24
AU2009201951A1 (en) 2009-06-04
CA2468248A1 (en) 2003-07-24
AU2009201956A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
JP5289281B2 (ja) Cns疾患の治療において使用するためのプレグナンステロイド
CN1270718C (zh) 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
WO2009142594A9 (en) The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
Claman Glucocorticosteroids II: the clinical responses
RU2413516C2 (ru) Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
US11026953B2 (en) 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
JP2022159475A (ja) 医学的治療における使用のための3-β-ヒドロキシ-5-α-プレグナン-20-オン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091005

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130828